Delving into the Latest Updates on Shenzhen Turier Biotech Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Digestive System Disorders

Respiratory Diseases

Synthetic peptide

Recombinant polypeptide

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	1

Top 5 Drug Type	Count

Synthetic peptide	3
Small molecule drug	1
Recombinant polypeptide	1

Top 5 Target	Count

EBP(EBP cholestenol delta-isomerase)	2
GCGR x GLP-1R	1
FN1(Fibronectin)	1

主要目的：评价注射用TB001在健康受试者单次及多次皮下注射给药后的安全性和耐受性。次要目的：评价注射用TB001在健康受试者单次及多次皮下注射给药后的药代动力学（PK）特征。评价注射用TB001在健康受试者单次及多次皮下注射给药后的潜在药效学特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of TB001 for injection after single and multiple subcutaneous injections in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of TB001 for injection after single and multiple subcutaneous injections in healthy subjects. To evaluate the potential pharmacodynamic characteristics of TB001 for injection after single and multiple subcutaneous injections in healthy subjects.

Start Date10 Jan 2022

Sponsor / Collaborator

Qingyuan Tuwei Anchuang Technology Development Co., Ltd.

NCT05308940 / CompletedPhase 1

A Phase 1, Single and Multiple Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TB001 Injection in Healthy Subjects

It was a randomized, double-blind, placebo-controlled combined single ascending dose (SAD) and multiple ascending dose (MAD) study, evaluating the safety, tolerability and pharmacokinetics of TB001 after single and multiple subcutaneous injections in healthy subjects.

Start Date10 Jan 2022

Sponsor / Collaborator

Shenzhen Turier Biotech Co., Ltd.

CTR20213310 / CompletedPhase 1

注射用TB001在健康受试者的单次及多次皮下注射给药后的安全性、耐受性及药代动力学的I期临床研究

[Translation] Phase I clinical study on the safety, tolerability and pharmacokinetics of TB001 for injection after single and multiple subcutaneous injections in healthy subjects

主要目的：评价注射用TB001在健康受试者单次及多次皮下注射给药后的安全性和耐受性。次要目的：评价注射用TB001在健康受试者单次及多次皮下注射给药后的药代动力学（PK）特征。评价注射用TB001在健康受试者单次及多次皮下注射给药后的潜在药效学特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of TB001 for injection after single and multiple subcutaneous injections in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of TB001 for injection after single and multiple subcutaneous injections in healthy subjects. To evaluate the potential pharmacodynamic characteristics of TB001 for injection after single and multiple subcutaneous injections in healthy subjects.

Start Date10 Jan 2022

Sponsor / Collaborator

Shenzhen Turier Biotech Co., Ltd.

100 Clinical Results associated with Shenzhen Turier Biotech Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Turier Biotech Co., Ltd.

Login to view more data

6

Literatures (Medical) associated with Shenzhen Turier Biotech Co., Ltd.

25 Jul 2024·Journal of Medicinal Chemistry

Discovery of Novel Peptide Antagonists Targeting GPR55 for Liver Inflammation and Fibrosis

Article

Author: Wu, Shuohan ; Song, Nazi ; Tang, Qinglin ; Chan, Albert S. C. ; Luo, Suijia ; Liu, Han ; Cai, Xiaoqing ; Li, Haonan ; Liu, Xianyan ; Shi, Zihan ; Jiang, Xianxing

Liver fibrosis is a condition characterized by aberrant proliferation of connective tissue in the liver resulting from diverse etiological factors. G protein-coupled receptor GPR55 has recently been identified as a regulator of liver diseases. Herein, we report the discovery of a cyclic peptide P1-1 that antagonizes GPR55 and suppresses collagen secretion in hepatic stellate cells. The alanine scanning and docking study was carried out to predict the binding mode and allowed for further structural optimization of peptide antagonists for GPR55. The subsequent in vivo study demonstrated that P1-1 ameliorates CCl₄-induce and MCD-diet-induce acute liver inflammation and fibrosis. Further study indicates that P1-1 reduces reactive oxygen species (ROS) production, attenuates ER stress, and inhibits mitochondria-associated hepatocyte apoptosis. In this work, we provided the first successful example of antagonizing GPR55 for liver inflammation and fibrosis, which validates GPR55 as a promising target for the treatment of liver fibrosis and affords a high-potent GPR55 antagonist P1-1 as a potential therapeutic candidate.

25 Apr 2024·Journal of Medicinal Chemistry

Design and Synthesis of Novel Ultralong-Acting Peptides as EDP-EBP Interaction Inhibitors for Pulmonary Fibrosis Treatment

Article

Author: Jiang, Xianxing ; Liu, Han ; Wang, Yixiang ; Liu, Qi ; Cheng, Wei ; Zhao, Qian ; Li, Yu ; Xue, Fanghan ; Tang, Qinglin ; Song, Nazi ; Shi, Zihan ; Zhang, Fangfang ; Wang, Yiqing

The increased remodeling of the extracellular matrix (ECM) in pulmonary fibrosis (PF) generates bioactive ECM fragments called matricryptins, which include elastin-derived peptides (EDPs). The interaction between EDPs and their receptors, including elastin-binding protein (EBP), plays a crucial role in exacerbating fibrosis. Here, we present L_XJ-02 for the first time, a novel ultralong-acting inhibitor that disrupts the EDPs/EBP peptide-protein interaction, promoting macrophages to secrete matrix metalloproteinase-12 (MMP-12), and showing great promise as a stable peptide. MMP-12 has traditionally been implicated in promoting inflammation and fibrosis in various acute and chronic diseases. However, we reveal a novel role of L_XJ-02 that activates the macrophage-MMP-12 axis to increase MMP-12 expression and degrade ECM components like elastin. This leads to the preventing of PF while also improving EDP-EBP interaction. L_XJ-02 effectively reverses PF in mouse models with minimal side effects, holding great promise as an excellent therapeutic agent for lung fibrosis.

13 Apr 2023·Journal of medicinal chemistryQ1 · MEDICINE

Design and Discovery of Novel Cyclic Peptides as EDPs-EBP Interaction Inhibitors for the Treatment of Liver Fibrosis.

Q1 · MEDICINE

Article

Author: Jiang, Xianxing ; Tang, Qinglin ; Li, Runkai ; Luo, Suijia ; Cai, Xiaoqing ; Song, Nazi ; Zhao, Qian ; Shi, Zihan ; Li, Haonan ; Chen, Yili

Liver fibrosis is the undesirable result of excessive deposition of the extracellular matrix (ECM), and elastin is known as one of the key ECM components. Under specific pathological conditions, elastin undergoes degradation to produce elastin-derived peptides (EDPs), which bind to elastin-binding protein (EBP) to activate corresponding signal pathways, thus accelerating fibrosis progression. Herein, we describe the discovery of novel cyclic peptides that function as potent and stable inhibitors to interfere with the peptide-protein interaction between EDPs and EBP. Remarkably, C_XJ-2 exhibited potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. The subsequent in vivo study demonstrated that C_XJ-2 possessed potent antifibrotic efficacy in ameliorating CCl₄-induced liver fibrosis. This work provides a successful pharmacological strategy for the development of novel inhibitors of EDPs-EBP interaction, which sheds new light on how cyclic peptides disrupt peptide-protein interaction and may also provide new structure-oriented therapeutic candidates in liver fibrosis.

100 Deals associated with Shenzhen Turier Biotech Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Turier Biotech Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Preclinical

IND Approval

1

Phase 1 Clinical

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TB-001 ( GCGR x GLP-1R )	Hepatitis B, Chronic More	Phase 2
TB-B002D	Idiopathic Pulmonary Fibrosis More	Phase 1
TB-D004C	Diabetic Nephropathies More	IND Approval
CXJ-2 ( EBP )	Fibrosis, Liver More	Preclinical
LXJ-02 ( EBP )	Pulmonary Fibrosis More	Preclinical